RACA

Therapeutics Acquisition Corp. (RACA) | Rumor.io

Therapeutics Acquisition

RACA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RACA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% +0

Oct 22

A proposal to launch a DAO-run exchange for RACA could strengthen its value by using trading fees to buy back and lock RACA tokens.
This exchange would create a self-sustaining ecosystem with sustainable price growth, stronger incentives for long-term holders, and greater trust and transparency.
RACA is showing bullish volatility on Kucoin's radar, with a 17.26% increase in price, but is also among the top losers on Okx Spot with a -0.74% decline.

Generated by AI

Sentiment

Of the messages about RACA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	31.43%
Bearish	—	—	—	68.57%

Oct 27

$RACA has shown a 35% increase without leverage, with an entry point of 0.0001559.
The asset has the potential for a 5x increase, with a target price of 0.0013.
$RACA is expected to continue its uptrend, with a strong momentum and a growing potential for success.

Generated by AI

Topics

Of the messages about RACA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	38.77%
Announcements	0%	0%	0%	3.08%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	100%	100%	100%	40.97%
Technical Analysis	0%	0%	0%	17.18%

Dec 9

Therapeutics Acquisition Corp. (RACA) has been listed on OKEx, with native token and Metamon game available for trading.
The project has received positive feedback from supporters, with many praising its innovative approach and potential for success.
Some users have expressed enthusiasm for the project's future prospects, with one user calling it a "Fantastic project with great potential".

Generated by AI

Community

Of the messages about RACA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Mar 15

The merger between Therapeutics Acquisition Corp. ($RACA) and POINT Biopharma will have an implied equity value of $924 million.
POINT Biopharma is expected to receive approximately $300 million in proceeds from the merger and will list on NASDAQ through the deal.
The deal's pro-forma equity value is $924M, with a PIPE investment of $165M and ownership of 14% by the PIPE investors.

Generated by AI

Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...

2mo agoYahoo Finance

Also Discussed

Investors talking about RACA also mention

#	Name	Attention
1	Primis Financial Corp.FRST	0%0
2	Orion S.A.OEC	0%0
3	U.S. Cellular CorporationUSM	0%new
4	PBY - Prospect Capital Corporation	——
5	Independence Realty Trust Inc.IRT	0%new
6	HHRS - Hammerhead Energy Inc.	——
7	Veea Inc.VEEA	0%0
8	Seaport Entertainment Group, Inc.SEG	0%new
9	Freedom Day Dividend ETFMBOX	0.01%new
10	The Hanover Insurance Group, Inc.THG	0%0